A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases (NCT04511013)
A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
🩺 Plain-English Summary (8th-Grade Level)
This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Ipilimumab and nivolumab are monoclonal antibodies that may interfere with the ability of tumor cells to grow and spread. This trial aims to find out which approach is more effective in shrinking and controlling brain metastases from melanoma.
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (331 Sites)
Showing the first 25 of 331 sites.
- University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Thomas Hospital — Fairhope, Alabama
- Mobile Infirmary Medical Center — Mobile, Alabama
- Anchorage Associates in Radiation Medicine — Anchorage, Alaska
- Anchorage Radiation Therapy Center — Anchorage, Alaska
- Alaska Breast Care and Surgery LLC — Anchorage, Alaska
- Alaska Oncology and Hematology LLC — Anchorage, Alaska
- Alaska Women's Cancer Care — Anchorage, Alaska
- Anchorage Oncology Centre — Anchorage, Alaska
- Katmai Oncology Group — Anchorage, Alaska
- Providence Alaska Medical Center — Anchorage, Alaska
- Fairbanks Memorial Hospital — Fairbanks, Alaska
- Mercy Hospital Fort Smith — Fort Smith, Arkansas
- Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
- Epic Care-Dublin — Dublin, California
- Bay Area Breast Surgeons Inc — Emeryville, California
- Epic Care Partners in Cancer Care — Emeryville, California
- UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California
- Contra Costa Regional Medical Center — Martinez, California
- Providence Queen of The Valley — Napa, California
- Alta Bates Summit Medical Center - Summit Campus — Oakland, California
- Bay Area Tumor Institute — Oakland, California
- Sharp Memorial Hospital — San Diego, California
- Providence Medical Foundation - Santa Rosa — Santa Rosa, California
- Providence Santa Rosa Memorial Hospital — Santa Rosa, California
📞 Contact the Study Coordinator
Phone: (210) 614-8808
Email: cmireles@swog.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Acral Lentiginous Melanoma
- Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease — Houston, Texas
- A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma — Birmingham, Alabama
- Dinaciclib in Treating Patients With Stage IV Melanoma — Mobile, Alabama
Explore by condition: All Acral Lentiginous Melanoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.